RightRep EN · PT Open the app
BLOG

Can You Train With a Blood Clot (DVT)? The Walk-Don't-Bed-Rest Audit: The Door Where the Hospital's Oldest Instruction — Rest the Leg, Move Nothing — Was Randomized Against Its Own Opposite and Lost (Partsch's 45-Patient Trial: The Walking Groups Covered 600–12,000 m a Day in Compression While the Bed-Rest Group Managed 66, Pain Falling From Day 2 Versus Day 9, New Pulmonary Emboli No Different, Clinical Scores Better P<.01), the Meta-Analysis Column at 13 Studies and 3,269 Patients Concurring (Early Ambulation on Anticoagulation: No More New Emboli, No More Progression, No More Clot Deaths — and Better Pain Remission SMD 0.42), Where the Prevention Column Reads Like a Gym Membership Ad (MEGA at 3,608 Patients Against 4,252 Controls: Regular Sport OR 0.71, Protective at Every Frequency, Intensity and Type — the Muscle Pump Is the Antidote to Clots, Not Their Trigger), the Chronic-Leg File Carries the Field's Honest Fight (Brandjes' Made-to-Measure Stockings Cutting Post-Thrombotic Syndrome 20% vs 47%, Severe 11% vs 23%; SOX's 806-Patient Placebo Null at 14.2% vs 12.7%; and Kahn's Exercise RCT Improving the Already-Damaged Leg VEINES-QOL +4.6 P=.027), and the Lifter Owns Two Doors Nobody Else at This Gym Door Owns (Effort Thrombosis of the Arm — Weight Lifting the #2 Sport Behind Baseball in 123 Athlete Cases, Return at 4.7 Months — and the 11-Year Anabolic-Steroid Cohort Pricing the Syringe at VTE aHR 2.42, Between Its Myocardial Infarctions at 3.00 and Its Arrhythmias at 2.26) — the Answer Is Anticoagulation First, Walking in Compression Now, and the Barbell Returns on a Calendar, Not a Feeling

By RightRep AI Assistant · · 24 min read

A deep-vein thrombosis is the file where the internet's two default scripts — the glass-leg script: the clot is a loose bullet, the leg is a loaded trap, rest until it dissolves or it flies to your lungs and the denial script: it's a swollen calf, movement is medicine for everything, train through it — both fail the reader at the exact door she walked in through, because this reader already has the ultrasound report and the anticoagulation box on the counter, and asks a specific question: when does the gym come back — does walking dislodge the clot, does the barbell have to wait months, and did the training have anything to do with this? The glass-leg script dies on the trial file, because the instruction it enforces — bed rest — was randomized against its own opposite and lost: in Partsch's trial the walking groups covered 600 to 12,000 meters a day in compression bandages while the bed-rest group averaged 66, pain fell from day 2 versus day 9, and new pulmonary emboli were no different [1]; the meta-analysis column at 13 studies and 3,269 patients printed the same verdict — early ambulation on anticoagulation produced no more new emboli, no more clot progression, no more clot deaths, and better pain remission [2]. The denial script dies on two columns further down the file: the effort-thrombosis door, where the sport itself — repetitive overhead lifting — is the named trigger in 123 athlete cases [9][4], and the anabolic-steroid cohort, where 1,189 users followed eleven years against 59,450 controls carried VTE aHR 2.42 [11]. So the fences come first. First: the emergency fence — new breathlessness, chest pain, coughing blood or fainting is the clot's dangerous address (pulmonary embolism), and that is the emergency department today, not a training question [10]. Second: the undiagnosed fence — a suspected clot (one swollen, hot calf) gets the ultrasound before the program; this file is written for the reader with the confirmed clot and treatment started [10]. Third: the calendar fence — the acute phase's plan belongs to the clinician who prescribed the anticoagulation; this file builds fences around that plan, never over it [10]. Fourth: the trend fence — a leg that swells more, hurts more or discolors while on treatment is a same-week call to the same clinician, not a training variable [10]. With the fences standing, the file underneath is one of the cleanest inversions in this library's health wing: the treatment for the blood clot is walking, the prevention for the next one is training, and only the syringe and the overhead-heavy arm actually indict the gym [1][2][3][9][11].

The short answer: yes — the day treatment starts you walk; the barbell returns on a calendar, not a feeling

Strip the file to its spine. The bed-rest instruction, tested: Partsch randomized 45 patients with ultrasound-proven proximal DVT — all on the same low-molecular-weight heparin — to inelastic compression bandages, class-II compression stockings, or bed rest without compression: the walking groups logged 600–12,000 m a day against the bed-rest group's 66 m average, pain dropped significantly from the second day versus only after nine, leg circumference followed the same curve, clinical scores favored the walkers (P<.01), and the safety columns — new pulmonary emboli and thrombus regression — showed no significant difference, with femoral-vein progression if anything more frequent in the bed-rest arm [1]. The verdict, pooled: thirteen studies and 3,269 patients later, the meta-analysis found early ambulation with standard anticoagulation not associated with a higher incidence of new PE, DVT progression or DVT-related deaths, and associated with better acute-pain remission (SMD 0.42, 0.09–0.74, P=.01) [2]. The prevention column: the MEGA case-control put 3,608 clot patients against 4,252 controls — regular sports participation ran 31.5% versus 39.7%, an odds ratio of 0.64 (0.58–0.71), adjusting to 0.71 (0.64–0.78) for sex, age and body mass index, holding at 0.67 in healthy individuals alone, and no frequency, intensity or type of sport broke the protection [3]. The chronic-leg column: for the leg already damaged by a past clot, a six-month trainer-supervised exercise program improved venous disease-specific quality of life over control (VEINES-QOL difference +4.6, 0.54–8.7, P=.027) with severity trending the same way [7]. The calendar column: most first clots get around three months of anticoagulation, then a gradual return to play on clinical clearance — some readers will stay on anticoagulation long-term, and even collision sports get negotiated with timed dosing rather than forbidden [10]; the overhead-lifter's arm clot averages 4.7 months to sport return [9]. That is the audit in one paragraph: this reader's program does not start when the fear leaves — it starts with walking the day treatment does, and loads a barbell when the calendar and the clinician agree [1][2][10].

What the condition actually is: a stuck-drainage story — and the calf is the pump that reopens the road

The mechanics in a paragraph: the deep veins of the leg are a low-pressure return network with one-way valves, and they have no heart of their own — blood climbs out of the calf by the squeeze of the calf and thigh muscles, the stir of the ankle, and the one-way valves that keep it climbing [1][13]. A thrombus is a dam in that network — formed where flow stalls (immobility, surgery, a long flight, a hypercoagulable state), it backs fluid into the leg: the swelling, the heat, the pain on squeeze [10][13]. Anticoagulation does not dissolve the dam by force — it stops the dam growing, and the body's own fibrinolytic crews dismantle it over weeks to months; that is why the treatment calendar, not the pain level, is the real clock [10][13]. Two consequences follow, and both favor the gym. First, the muscle pump is not a threat to this system — it is the system's engine: Partsch's walkers did not scatter their clots; they drained their legs faster, and the circumference column moved with the walking, not against it [1][2]. Second, the deep danger of a DVT is not the gym — it is the clot's address: the piece that reaches the lungs (pulmonary embolism) is the event every fence in this file exists to catch early, and the recurrence file runs on calendar rules, not fear rules — low-risk women off anticoagulation after a first unprovoked clot recurred at 3.0% per patient-year (1.8–4.8) against 8.1% in high-risk stoppers and 1.6% in continuers [12]. And the quiet sequel that makes the early weeks matter: post-thrombotic syndrome — the chronically swelling, aching, sometimes ulcerating leg a badly-drained thrombosis leaves behind — strikes by location, 51.1% (39.5–62.7) after iliofemoral clots, 30.7% after femoropopliteal, 22.8% after distal, in the pooled file of 49 studies and 14,171 patients [8]. The reader told to "rest the leg" has the physiology exactly backwards: the leg empties on muscle work, and the trial that tested the question put the walking in the prescription [1][2].

The history column: the bed-rest era, and the 2000 trial that retired it

Every audit in this library starts by taking the folklore seriously, and this folklore was hospital policy, not just gym-talk: for most of the twentieth century the acute deep-vein thrombosis got bed rest — days to weeks of it, on the theory that a moving leg pumped clot fragments toward the lungs and a still leg let the dam seal [1]. The randomized test came in 2000: Partsch and Blättler took 45 patients with proximal DVT proven on compression ultrasound or phlebography, all treated with the same dalteparin regimen, and randomized fifteen apiece to inelastic compression bandages (Unna boots), class-II thigh-length stockings, or bed rest without compression — the trial's own design placing the folklore and the inversion in adjacent rooms [1]. The results read like the door's whole argument compressed to nine days: daily walking distance of 600–12,000 m in the compression groups versus 66 m averaged by the bed-rest group; pain falling significantly from the second day in the walkers and only after the ninth day at rest; leg circumference following the same curve; clinical scores better in the walkers (P<.01) — and the safety columns flat: no significant difference in new pulmonary emboli or thrombus regression, with progression in the femoral vein greater and more frequent in the bed-rest group (not significant, but pointed the wrong way for the folklore) [1]. The authors' conclusion prints the way this library likes it: mobile patients with acute proximal DVT on low-molecular-weight heparin should be encouraged to walk with compression, because pain and swelling resolve faster and the risk of pulmonary embolism is not significantly increased [1]. The trial was small and honest about it [1]. What followed it was the pooling that made it policy — and that is the next column [2].

The safety column: the meta-analysis that settled walking

One trial of 45 patients retires no dogma by itself, so the column that closed the question is Liu's 2015 meta-analysis: thirteen studies, 3,269 patients, bed rest versus early ambulation, all with standard anticoagulation [2]. The pooled safety verdict has three flat lines — early ambulation was not associated with a higher incidence of new pulmonary embolism, progression of DVT, or DVT-related deaths — and one that breaks the expected direction: among patients starting with moderate or severe pain, the early-ambulation arm achieved better remission of acute pain in the affected limb (SMD 0.42, 95% CI 0.09–0.74, P=.01) [2]. Read that column the way the return-to-play file reads it: the feared mechanism — walking shakes the clot loose — was measured where it would show, and did not show; the measured walking effect went the other way, on both pain and drainage [1][2]. The honest footnote is heterogeneity: the edema-remission pool could not reach a solid conclusion across the few studies reporting it, and the underlying trials vary in compression regimens and endpoints [2]. But the direction of the file is not in doubt, and the guidance it produced — the 2022 athlete-management review's one-line version is gradual return to play after treatment is complete, on the clinician's calendar — stands on exactly this column [2][10].

The prevention column: the MEGA inversion — the muscle pump as prophylaxis

The reader at this door often arrives with a second, quieter question: did my training cause this? The MEGA case-control — the Leiden group's mega-study of venous thrombosis risk, 3,608 patients against 4,252 control subjects — answered it by asking the controls the same sports questions as the patients [3]. The result is the prevention column's whole spine: 31.5% of the clot patients participated in sports versus 39.7% of the controls — an odds ratio of 0.64 (0.58–0.71) — adjusting to 0.71 (0.64–0.78) for sex, age and BMI, and holding at 0.67 (0.58–0.78) when the analysis was restricted to healthy individuals [3]. And the dose table the fear-theorist needs: no differences in risk were found for various frequencies, intensities and types of sport — protection did not evaporate at high intensity, did not depend on the modality, and did not curve back up anywhere in the measured range [3]. That is the athlete paradox dissolved: training does not sit on a cliff edge above which veins clot — immobility is the risk factor in this file, and muscle work is the antidote, which is precisely why the hospital's own clot-prevention apparatus is a prescription for moving: post-surgery mobilization, hourly walking, compression pumps that imitate a calf [1][3][13]. The one honest exception lives in the arm, not the leg, and it gets its own column below [4][9].

The chronic-leg column: what the leg becomes, and the field's honest fight over the stocking

The acute question — can I walk? — settles in nine days [1][2]. The chronic question — what does this leg become? — is where the file gets interesting, because post-thrombotic syndrome is the outcome that matters at year two [8]. The pooled risk spine: 49 studies, 14,171 patients — PTS in 51.1% (39.5–62.7) after iliofemoral thrombosis, 30.7% (21.4–39.9) after femoropopliteal, 22.8% (17.1–29.8) after distal, with an estimated 250,000 new PTS cases a year in Europe and 4.86 million people living with it [8]. Against that background, the stocking file is the field's honest fight, and this audit prints both sides. The Brandjes trial, 1997: 194 patients with a first proximal DVT randomized to made-to-measure graded compression stockings for at least two years or none — mild-to-moderate PTS 20% vs 47%, severe PTS 11% vs 23%, both P<0.001, most cases arriving within 24 months of the clot [5]. The SOX trial, 2014: 806 patients randomized to active versus placebo elastic compression stockings for two years — PTS 14.2% vs 12.7%, center-adjusted HR 1.13 (0.73–1.76), P=.58, per-protocol no better, and the authors' verdict that the findings do not support routine wearing [6]. Two landmark trials, opposite verdicts — the audit's honest reading is that the stocking decision is genuinely contested between them, which is why this file routes it to the prescribing clinician rather than to folklore in either direction: if stockings are prescribed, the Partsch logic says wear them while walking [1][5][6]. What is not contested is the column that comes next: once the leg already hurts, exercise is one of the few levers that has been randomized [7].

The treatment column: the exercise RCT for the leg that already hurts

For the reader months or years past the clot, dragging a heavy, aching leg, the file's most practical study is Kahn's 2011 randomized trial: 43 patients with post-thrombotic syndrome, two centers, six months of trainer-supervised exercise training versus an education session with monthly phone calls [7]. The primary quality-of-life column moved: VEINES-QOL improved +6.0 points in the training arm versus +1.4 in control — difference 4.6 (95% CI 0.54–8.7, P=.027) — and most secondary outcomes favored training, with the Villalta severity score trending the right way (−3.6 vs −1.6; difference −2.0, −4.6 to 0.6, P=.14 — honest null, printed as such) [7]. The honest framing is in the authors' own verb: may improve — this was a pilot-sized trial, powered to justify the definitive multicenter version [7]. But it stands on the right physiology (the muscle pump draining the damaged network [1]) and in the right direction as the only randomized exercise lever this population has [7]. Beside it runs the anticoagulation-calendar column the same research group built: HERDOO2, validated prospectively in 2,785 patients across 44 centers in seven countries — women with none or one of the rule's criteria (hyperpigmentation, edema or redness; D-dimer ≥250 μg/L; obesity; age ≥65) discontinued anticoagulants after short-term treatment and recurred at 3.0% per patient-year (1.8–4.8), against 8.1% (5.2–11.9) in high-risk patients who stopped and 1.6% (1.1–2.3) in those who continued [12]. Translation for the training reader: the stop-or-continue decision is a scored, validated rule your hematologist runs — it is not a judgment about your discipline, and it is not a reason to self-taper [12].

The lifter's two doors: the arm clot, and the syringe

This file owns two columns no other gym door owns, and both belong to the lifter specifically. Door one — effort thrombosis (Paget-Schroetter syndrome): an axillosubclavian vein thrombosis born of repetitive overhead abduction and external rotation compressing the vein at the thoracic outlet — the young athlete's swollen, blue-ish arm after bench, presses or throwing work [9]. The systematic review of athlete cases is direct: of 123 published cases, baseball led at 26.8% and weight lifting came second at 19%, ahead of swimming, football and basketball; average return to sport ran 4.7 months; 26.7% reported complications — most commonly pulmonary embolism [9]. The MEGA group's sub-analysis had already priced the mechanism in the general population: strenuous sport activities involving the upper extremities increase the risk of venous thrombosis of the arm [4]. The programming lesson is narrow and important: this is the one door in the file where the training itself is the named trigger — a lifter's acutely swollen arm is a vascular consultation before it is a deload, and the return runs through decompression surgery and anticoagulation decisions that belong to specialists [9]. Door two — the syringe: the 11-year cohort following 1,189 anabolic-androgenic steroid users against 59,450 controls put the file's only genuine gym-bought clot risk on the table — venous thromboembolism aHR 2.42 (1.54–3.80), sitting in a ledger with acute myocardial infarction aHR 3.00 (1.67–5.39), revascularization 2.95, arrhythmia 2.26, cardiomyopathy 8.90 and heart failure 3.63 [11]. Against MEGA's protective 0.71 for natural training [3], the syringe column is the file's starkest contrast — the one habit at this door that buys clots instead of preventing them [11].

The honest-null column: what this file cannot yet promise

This library's audits earn their keep on the nulls, and this one carries four. The stocking null: SOX's placebo-controlled 806 patients found no routine benefit (14.2% vs 12.7%, HR 1.13) [6] — printed against Brandjes' 20% vs 47% [5] rather than hidden, because the field itself has not settled it. The severity null: in the exercise RCT, the Villalta severity difference missed significance (P=.14) while quality of life moved (P=.027) — training improved the life the leg lives, with the severity trend honest but unproven at pilot size [7]. The load null: no trial has randomized maximal barbell loading mid-anticoagulation — the return-to-lift calendar runs on the return-to-play framework [10], the 4.7-month Paget-Schroetter average [9] and clinician judgment, and this file says so plainly instead of extrapolating. And the data null: the global-burden review found reliable VTE incidence data for only a handful of regions — global DVT incidence spanning 25.1 to 131.5 per 100,000, PE 30-day mortality 1.0–9.0%, one-year recurrence 2.9–8.1% — a reminder that the surveillance floor under this file is thinner than the guideline confidence above it [13]. What is not a null: the bed-rest hypothesis — the instruction this door's folklore enforces — is a two-trial, one-meta, twenty-five-year dead hypothesis [1][2].

The program in gym terms: what walks now, what ramps, what stops

Walks now: the day anticoagulation is running and the clinician's plan allows, the prescription is Partsch's — daily walking in the prescribed compression, pain-limited, building on the ordinary week [1][2]. Walking is not the compromise version of training at this door; it is the treatment column [1][2].

Ramps the barbell on the calendar, not a feeling: most first clots finish roughly a three-month anticoagulation course, and the return-to-play file is explicit — gradual, after treatment completes, on clinical clearance, some readers negotiating long-term anticoagulation and even collision sports with timed dosing [10]. The ramp itself is the ordinary overload ladder from light, with machines anchoring confidence while the leg recalibrates — and the breathing file governing breath under load the way it always did.

Treats the swollen arm as a different door: an acutely swollen arm in an overhead lifter is effort thrombosis until imaging says otherwise — vascular consult first, program second, return averaged 4.7 months in the athlete file [9][4].

Stops and refers: new breathlessness, chest pain, coughing blood or fainting — emergency department today [10]; a leg trending worse on treatment — same-week call [10]; the swollen-but-undiagnosed calf — ultrasound before programming [10]; and the reader on the syringe whose real question is the clot — the file's answer is the cohort's ledger, not a training tweak [11].

Keeps one dated ledger: morning-versus-evening swelling notes, walking distance, load on the bar, medication timing — one timeline. It is how a return gets steered instead of guessed [1][7][10]. The sick-day and surgery gaps route through the when-you're-ill door; the cardiology cousin's calendar lives at the heart-attack door; and the drainage-twin of this file — the lymphatic one — is the lymphedema door.

The Brazil anchors: PROTEV's 56.9%, and the file a hospital-system column rounds

The pt-BR twin of this file exists for a Brazilian audience standing in a system whose thrombosis-prevention floor is still being poured, with the local anchor the sweep's Brazil column runs on. The system file: PROTEV Brazil — the national survey of VTE prophylaxis protocols across Brazilian hospitals — found risk assessment by the Brazilian guideline, Padua or Caprini scores happening in the electronic record at 56.9% of hospitals, as a mandatory step at 45.1%, and pre-discharge risk reassessment at only 25% — the authors' own reading being that systematic risk assessment still does not occur for most patients [14]. Translation for the training reader: the prevention apparatus this file takes for granted is unevenly installed in the very system that will treat the clot — which raises, not lowers, the value of the reader knowing the fences (the swollen calf gets the ultrasound; the swollen arm gets the specialist; the leg on treatment that worsens gets the call) [10][14]. The data file: the global-burden review's regional-gaps column covers Latin America too — reliable incidence data from only a narrow band of countries — so the Brazilian reader's numbers ride on the pooled global file rather than a national registry [13]. The lymphedema file already carries Brazil's drainage-twin epidemiology; this file adds the system column.

So what do you actually do? The practical file

Six rules, every one sourced from the columns above:

  1. Sort the address first. Breathlessness, chest pain, coughing blood, fainting — the emergency department, today [10]. A suspected new clot — one swollen hot calf or a lifter's swollen arm — is imaging before it is a program [9][10].
  2. Walk the day the plan says walk. The randomized file put walking ahead of bed rest on pain (day 2 vs day 9), drainage and clinical scores, with no excess emboli [1] — and the pooled 3,269-patient column concurs [2]. In the compression that was prescribed, pain-limited, daily.
  3. Let the calendar, not the fear, return the barbell. Most first clots run ~3 months of anticoagulation; return-to-play is gradual and clinician-cleared after treatment [10]; the arm-clot average ran 4.7 months [9]. The stop-or-continue decision runs on validated rules like HERDOO2, not on how good the leg feels [12].
  4. Wear what was prescribed, and let the clinicians argue the rest. The stocking file is a genuine 20%-vs-47% [5] against a placebo null [6] — your prescription is the settled part; the guideline fight is theirs.
  5. Know the two doors that actually indict training. The overhead-heavy arm [4][9] and the syringe (VTE aHR 2.42 [11]) — everything else in this file exonerates the gym, with MEGA's protective 0.71 across every frequency, intensity and type [3].
  6. Keep the ledger. Swelling, walking, load, medication timing on one dated line — the steering instrument the whole return runs on [1][7][10].

How RightRep fits into this

The DVT file is, at its core, a calendar-versus-fear question — walking doses that start the day treatment does, a barbell that returns on a dated ramp, and a leg that has to be read by trend rather than by feel — and neither side of that ledger is answerable from memory:

  • The walking-dose machine. The treatment column of this file is daily, progressive walking [1][2] — a logged, distance-counted habit is the prescription's adherence instrument.
  • The return calendar made visible. "Gradual return after treatment completes" [10] is the overload ladder restarted from light — every session's actual loads recorded, not remembered, so the ramp is steered against the clinician's milestones.
  • The ledger dated. Swelling notes and load on one timeline separate a bad week from a bad trend — the difference between a deload and a phone call [10].
  • The form-checking loop on the comeback. Months off change movement patterns; camera-scored reps hold the technique standard while the leg and the arm recalibrate — the external eye at exactly the moment form drifts cheapest.
  • The habit column the prevention file prices. MEGA's protection is a regular-training effect [3] — and a tracked, counted training week is the habit's receipt.

The bottom line

  • The history column: bed rest was the instruction; Partsch 2000 randomized 45 proximal-DVT patients to walk 600–12,000 m/day in compression vs 66 m at rest — pain down from day 2 vs day 9, clinical scores better (P<.01), no excess new PE [1].
  • The safety column: Liu's meta — 13 studies, 3,269 patients — early ambulation on anticoagulation: no more new PE, progression or clot deaths; better pain remission (SMD 0.42, P=.01) [2].
  • The prevention column: MEGA — 3,608 patients vs 4,252 controls — regular sport OR 0.64, adjusted 0.71 (0.64–0.78), protective at every frequency, intensity and type [3].
  • The chronic-leg column: PTS by location — 51.1% iliofemoral / 30.7% femoropopliteal / 22.8% distal, 4.86M prevalent in Europe [8]; the stocking fight — Brandjes 20% vs 47%, severe 11% vs 23% [5] against SOX's placebo null 14.2% vs 12.7%, HR 1.13 [6].
  • The treatment column: six months of supervised exercise improved the post-thrombotic leg's VEINES-QOL +4.6 (0.54–8.7, P=.027), severity trend honest-null at P=.14 [7]; HERDOO2 puts low-risk women safely off anticoagulants at 3.0%/patient-year vs 8.1% high-risk stoppers [12].
  • The lifter's doors: weight lifting the #2 sport (19%) in 123 athlete Paget-Schroetter cases, return averaging 4.7 months, complications 26.7% — most commonly PE [9]; strenuous upper-extremity sport raises arm-thrombosis risk [4].
  • The syringe column: 1,189 AAS users vs 59,450 controls over ~11 years — VTE aHR 2.42 (1.54–3.80), in a ledger with MI 3.00 and cardiomyopathy 8.90 [11].
  • The honest nulls: SOX [6], the Villalta P=.14 [7], no trial of maximal loading mid-anticoagulation (the calendar runs on framework [10]), and the global data gaps (DVT incidence 25.1–131.5/100,000; PE 30-day mortality 1.0–9.0%) [13].
  • The Brazil anchor: PROTEV — risk assessment in the EHR at 56.9% of hospitals, mandatory at 45.1%, pre-discharge reassessment at 25% [14].

Walk the day the plan says walk, load the bar the day the calendar says load — and let the camera count the reps of the comeback at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. Journal of Vascular Surgery, 2000;32(5):861–869. pubmed.ncbi.nlm.nih.gov
  2. Liu Z, Tao X, Chen Y, Fan Z, Li Y. Bed rest versus early ambulation with standard anticoagulation in the management of deep vein thrombosis: a meta-analysis. PLoS One, 2015;10(4):e0121388. pubmed.ncbi.nlm.nih.gov
  3. van Stralen KJ, Le Cessie S, Rosendaal FR, Doggen CJ. Regular sports activities decrease the risk of venous thrombosis. Journal of Thrombosis and Haemostasis, 2007;5(11):2186–2192. pubmed.ncbi.nlm.nih.gov
  4. van Stralen KJ, Blom JW, Doggen CJ, Rosendaal FR. Strenuous sport activities involving the upper extremities increase the risk of venous thrombosis of the arm. Journal of Thrombosis and Haemostasis, 2005;3(9):2110–2111. pubmed.ncbi.nlm.nih.gov
  5. Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. The Lancet, 1997;349(9054):759–762. pubmed.ncbi.nlm.nih.gov
  6. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. The Lancet, 2014;383(9920):880–888. pubmed.ncbi.nlm.nih.gov
  7. Kahn SR, Shrier I, Shapiro S, et al. Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. CMAJ, 2011;183(1):37–44. pubmed.ncbi.nlm.nih.gov
  8. Valerio L, Christodoulou KC, Abele C, et al. Postthrombotic syndrome: risk after deep vein thrombosis and estimates of its incidence and prevalence in Europe. Journal of Thrombosis and Haemostasis, 2026;24(5):1690–1699. pubmed.ncbi.nlm.nih.gov
  9. Keller RE, Croswell DP, Medina GIS, Cheng TTW, Oh LS. Paget-Schroetter syndrome in athletes: a comprehensive and systematic review. Journal of Shoulder and Elbow Surgery, 2020;29(11):2417–2425. pubmed.ncbi.nlm.nih.gov
  10. Brennan FH Jr. Diagnosis, management of, and return to play guidance for venous thromboembolism in athletes. Current Sports Medicine Reports, 2022;21(4):129–136. pubmed.ncbi.nlm.nih.gov
  11. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, et al. Cardiovascular disease in anabolic androgenic steroid users. Circulation, 2025;151(12):828–834. pubmed.ncbi.nlm.nih.gov
  12. Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ, 2017;356:j1065. pubmed.ncbi.nlm.nih.gov
  13. Bikdeli B, Rashedi S, Pfeferman M, et al. Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism. Nature Reviews Cardiology, 2026 (online ahead of print). pubmed.ncbi.nlm.nih.gov
  14. Rocha ATC, Pinheiro TB, de Souza PRSP, Marques MA. Venous thromboembolism prophylaxis protocols at Brazilian hospitals — PROTEV Brazil [article in Portuguese]. Jornal Vascular Brasileiro, 2020;19:e20190119. pubmed.ncbi.nlm.nih.gov